

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM745720

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	Security Agreement		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Omega Pharma Innovation & Development NV		08/02/2022	Limited Liability Company: BELGIUM
Perrigo Pharma International Designated Activity Company		08/02/2022	Designated Activity Company: IRELAND
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	JPMorgan Chase Bank, N.A., as Collateral Agent		
<b>Street Address:</b>	10 South Dearborn, Floor L2NM		
<b>City:</b>	Chicago		
<b>State/Country:</b>	ILLINOIS		
<b>Postal Code:</b>	60603		
<b>Entity Type:</b>	Bank: UNITED STATES		
<b>PROPERTY NUMBERS Total: 6</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	88483841	FORTE 5	
<b>Serial Number:</b>	88483827	FORTE FIVE	
<b>Serial Number:</b>	88389366	COLDREX	
<b>Serial Number:</b>	85733114	REHABELLYTATION	
<b>Serial Number:</b>	87836895		
<b>Serial Number:</b>	90316129	RELIEF GETS REAL	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	8009144240		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	800-713-0755		
<b>Email:</b>	Michael.Violet@wolterskluwer.com		
<b>Correspondent Name:</b>	CT Corporation		
<b>Address Line 1:</b>	4400 Easton Commons Way		
<b>Address Line 2:</b>	Suite 125		
<b>Address Line 4:</b>	Columbus, OHIO 43219		
<b>NAME OF SUBMITTER:</b>	Doris Ka		

OP \$165.00 88483841

<b>SIGNATURE:</b>	/Doris Ka/
<b>DATE SIGNED:</b>	08/03/2022
<b>Total Attachments: 6</b> source=Perrigo - Notice of Grant of Security Interest in Trademarks (non-US entities) (Executed)#page1.tif source=Perrigo - Notice of Grant of Security Interest in Trademarks (non-US entities) (Executed)#page2.tif source=Perrigo - Notice of Grant of Security Interest in Trademarks (non-US entities) (Executed)#page3.tif source=Perrigo - Notice of Grant of Security Interest in Trademarks (non-US entities) (Executed)#page4.tif source=Perrigo - Notice of Grant of Security Interest in Trademarks (non-US entities) (Executed)#page5.tif source=Perrigo - Notice of Grant of Security Interest in Trademarks (non-US entities) (Executed)#page6.tif	

### RECORDATION FORM COVER SHEET TRADEMARKS ONLY

To the Director of the U. S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

**1. Name of conveying party(ies):**

1. Omega Pharma Innovation & Development NV  
Limited Liability Company - Belgium  
2. Perrigo Pharma International Designated Activity Company  
Designated Activity Company - Ireland  
 Individual(s)  Association  
 Partnership  Limited Partnership  
 Corporation- State: \_\_\_\_\_  
 Other \_\_\_\_\_  
Citizenship (see guidelines) \_\_\_\_\_

Additional names of conveying parties attached?  Yes  No

**3. Nature of conveyance/Execution Date(s) :**

Execution Date(s) August 2, 2022  
 Assignment  Merger  
 Security Agreement  Change of Name  
 Other \_\_\_\_\_

**2. Name and address of receiving party(ies)**

Additional names, addresses, or citizenship attached?  Yes  No

Name: JPMogan Chase Bank, N.A., as Collateral Agent

Street Address: 10 South Dearborn, Floor L2NM

City: Chicago

State: IL

Country: USA Zip: 60603

Individual(s) Citizenship \_\_\_\_\_

Association Citizenship \_\_\_\_\_

Partnership Citizenship \_\_\_\_\_

Limited Partnership Citizenship \_\_\_\_\_

Corporation Citizenship \_\_\_\_\_

Other Bank Citizenship USA

If assignee is not domiciled in the United States, a domestic representative designation is attached:  Yes  No  
(Designations must be a separate document from assignment)

**4. Application number(s) or registration number(s) and identification or description of the Trademark.**

A. Trademark Application No.(s) \_\_\_\_\_ Text \_\_\_\_\_

B. Trademark Registration No.(s) \_\_\_\_\_  
see attached Schedule I

Additional sheet(s) attached?  Yes  No

C. Identification or Description of Trademark(s) (and Filing Date if Application or Registration Number is unknown):

**5. Name & address of party to whom correspondence concerning document should be mailed:**

Name: Doris Ka - Senior Paralegal (Intellectual Property)

Internal Address: Cahill Gordon & Reindel LLP

Street Address: 32 Old Slip

City: New York

State: NY Zip: 10005

Phone Number: (212) 701-3569

Docket Number: Perrigo (57320.2164)

Email Address: dka@cahill.com

**6. Total number of applications and registrations involved:**

**13**

**7. Total fee (37 CFR 2.6(b)(6) & 3.41) \$ \_\_\_\_\_**

Authorized to be charged to deposit account

Enclosed

**8. Payment Information:**

Deposit Account Number \_\_\_\_\_

Authorized User Name \_\_\_\_\_

**9. Signature:**

Doris Ka

Signature

August 3, 2022

Date

Doris Ka

Name of Person Signing

Total number of pages including cover sheet, attachments, and document:

**6**

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:  
Mail Stop Assignment Recordation Branch, Director of the USPTO, P.O. Box 1450, Alexandria, VA 22313-1450

**Notice of Grant of Security Interest in Trademarks**

NOTICE OF GRANT OF SECURITY INTEREST IN TRADEMARKS, dated as of August 2, 2022 (this “**Agreement**”), made by Omega Pharma Innovation & Development NV, a limited liability company incorporated under the laws of Belgium, and Perrigo Pharma International Designated Activity Company, a designated activity company incorporated under the laws of Ireland, (each a “**Pledgor**” and together, the “**Pledgors**”), in favor of JPMORGAN CHASE BANK N.A., as Collateral Agent (as defined below).

Reference is made to the Intellectual Property Security Agreement, dated as of August 2, 2022 (as amended, supplemented, increased, extended, renewed, refinanced, amended and restated or otherwise modified from time to time, the “**Intellectual Property Security Agreement**”), among each Pledgor listed on the signature pages thereto and each other Pledgor that becomes a party thereto after the date thereof and JPMORGAN CHASE BANK, N.A., as collateral agent (together with its successors and assigns in such capacity, the “**Collateral Agent**”) for the Secured Parties. The parties hereto agree as follows:

**SECTION 1. Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Intellectual Property Security Agreement. The rules of construction specified in Section 1.1(b) of the Intellectual Property Security Agreement also apply to this Agreement.

**SECTION 2. Grant of Security Interest.** As security for the payment and performance, as applicable, in full of its Obligations, each Pledgor pursuant to the Intellectual Property Security Agreement did, and hereby does, assign and pledge to the Collateral Agent, its successors and permitted assigns, for the benefit of the Secured Parties, a continuing security interest in all of such Pledgor’s right, title and interest in, to and under any and all of the following assets now owned or at any time hereafter acquired by such Pledgor or in which such Pledgor now has or at any time in the future may acquire any right, title or interest (collectively, but excluding any Excluded Property, the “**IP Collateral**”) all Trademarks of the United States of America, including those listed on Schedule I.

**SECTION 3. Intellectual Property Security Agreement.** The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the Intellectual Property Security Agreement. Each Pledgor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the Intellectual Property Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Intellectual Property Security Agreement, the terms of the Intellectual Property Security Agreement shall govern.


**SECTION 4. Counterparts.** This Agreement may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one contract. Delivery of an executed counterpart to this Agreement by facsimile or other electronic transmission shall be as effective as delivery of a manually signed original.

**SECTION 5. Governing Law.** **THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.**


[Signature Pages Follow]

IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the day and year first above written


OMEGA PHARMA INNOVATION &  
DEVELOPMENT NV

DocuSigned by:  
  
By \_\_\_\_\_  
Name: Ms Anja Van Winsberghe  
Title: Authorized Signatory

PERRIGO PHARMA INTERNATIONAL  
DESIGNATED ACTIVITY COMPANY

DocuSigned by:  
  
By \_\_\_\_\_  
Name: Sonia Hollies  
Title: Authorized Signatory

**JPMORGAN CHASE BANK N.A.**, as Collateral  
Agent

By:   
Name: Erik Barragan  
Title: Authorized Officer

Schedule I  
to Notice of Grant of Security Interest in Trademarks

Trademarks Owned by the Pledgors

U.S. Trademark Registrations

<b>Owner</b>	<b>Mark Name</b>	<b>Application Number</b>	<b>Registration Number</b>	<b>Jurisdiction</b>
Omega Pharma Innovation & Development NV	ABTEI	79259402	6015808 Intl. No. 1157127 (Status 66A)	U.S.
Omega Pharma Innovation & Development NV	FORTE 5	88483841		U.S.
Omega Pharma Innovation & Development NV	FORTE FIVE	88483827		U.S.
Omega Pharma Innovation & Development NV	LACTACYD	79259405	6015809 Intl. No. 1222984 (Status 66A)	U.S.
Omega Pharma Innovation & Development NV	PARANIX	79187745	5126475 Intl. No. 850274 (Status 66A)	U.S.
Omega Pharma Innovation & Development NV	PREVALIN	79192976	5229981 Intl. No. 1115851 (Status 66A)	U.S.
Omega Pharma Innovation & Development NV	XLS	79290232	6413604 Int. No. 0986470 (Status 66A)	U.S.
Omega Pharma Innovation & Development NV	ABTEI	79/259,402	6,015,808	U.S.
Omega Pharma Innovation & Development NV	FORTE 5	88/483,841		U.S.
Omega Pharma Innovation & Development NV	FORTE FIVE	88/483,827		U.S.
Omega Pharma Innovation & Development NV	LACTACYD	79/259,405	6,015,809	U.S.

Owner	Mark Name	Application Number	Registration Number	Jurisdiction
Omega Pharma Innovation & Development NV	XLS	79/290,232	6,413,604	U.S.
Perrigo Pharma International Designated Activity Company	NIQUITIN	79255618	5841903 Intl. No. 0866216 (Status 66A)	U.S.
Perrigo Pharma International Designated Activity Company	COLDREX	88389366		U.S.
Perrigo Pharma International Designated Activity Company	REHABELLYTATION	85733114	4752276	U.S.
Perrigo Pharma International Designated Activity Company	PREVACID blue and purple circles (device only)	87836895	5589855	U.S.
Perrigo Pharma International Designated Activity Company	COLDREX	88/389,366		U.S.
Perrigo Pharma International Designated Activity Company	PREVACID Logo	87/836,895	5,589,855	U.S.
Perrigo Pharma International Designated Activity Company	RELIEF GETS REAL	90/316,129		U.S.